Engineered Chiral Probiotics Ameliorate MASH via Gut–Liver Axis
Advanced Science · 04.11.2026
DOI: 10.1002/advs.78432 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 04.11.2026. Verfasst von Jing Chen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ultrasound, Zhongshan Hospital, Institute of Ultrasound in Medicine and Engineering, Fudan University, Shanghai, People's Republic of C…. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of the Ministry of Science and Technology of China, Shanghai Municipal Health Commission.
Abstract (Originalsprache)
The global epidemic of metabolic dysfunction‐associated steatohepatitis (MASH) is escalating without effective therapies. This study identified a significant depletion of the gut commensal bacterium Faecalibacterium duncaniae ( F. duncaniae ) as a core feature of MASH. To overcome the poor colonization by traditional probiotics in inflammatory environments, we engineered a living microbial therapeutic by incorporating chiral gold nanozymes onto F. duncaniae . We discovered that biological performance is enantiomer‐dependent: the right‐handed nanozyme (D‐Au) serves as a superior ROS‐scavenging shield, protecting the probiotic from oxidative assault and enhancing its colonization in the inflamed gut. In mouse models of MASH, this engineered probiotic (F@D‐Au) reversed disease progression, ameliorating steatosis, inflammation, and fibrosis. It further restored systemic homeostasis, rectifying dysbiosis, metabolic disturbances, and—notably—MASH‐associated cognitive impairment. Metabolomic analyses revealed that this multi‐organ benefit was linked to the restoration of key microbial metabolites, including kynurenic acid and linoleic acid. Our work establishes a new class of chirality‐enhanced living therapeutics that precisely remodel the gut–liver axis, offering a transformative strategy for treating MASH and its complications.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ultrasound, Zhongshan Hospital, Institute of Ultrasound in Medicine and Engineering, Fudan University, Shanghai, People's Republic of China.
- Department of Ultrasound, Zhuhai People's Hospital (The Affiliated Hospital of Beijing Institute of Technology, Zhuhai Clinical Medical College of Jinan University), Zhuhai, People's Republic of China.
- Department of Gastroenterology, Zhongshan Hospital, Fudan University, Shanghai, People's Republic of China.
- Department of Ultrasound, Huashan Hospital, Fudan University, Shanghai, People's Republic of China.
ORCID-Profile: Yuli Zhu, Heng Zhang, Huixiong Xu, Haohao Yin
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of the Ministry of Science and Technology of China
- Shanghai Municipal Health Commission
- Scientific Research and Development Fund of Zhongshan Hospital
- Shanghai Sailing Program
- China Postdoctoral Science Foundation
Zitieren
APA
Chen, J., Zhang, S., Zhu, Y., Zhou, D., Ji, C., Zhu, M., Wang, S., Shen, Y., Yu, J., Zhang, H., Fang, Y., Xu, H., & Yin, H. (2026). Engineered Chiral Probiotics Ameliorate MASH via Gut–Liver Axis. Advanced Science. https://doi.org/10.1002/advs.78432
Vancouver
Chen J, Zhang S, Zhu Y, Zhou D, Ji C, Zhu M, et al. Engineered Chiral Probiotics Ameliorate MASH via Gut–Liver Axis. Advanced Science. 2026. doi:10.1002/advs.78432
BibTeX
@article{Chen2026,
author = {Chen, Jing and Zhang, Shen and Zhu, Yuli and Zhou, Da and Ji, Chunya and Zhu, Mingrui and Wang, Sirui and Shen, Yuting and Yu, Jifeng and Zhang, Heng and Fang, Yan and Xu, Huixiong and Yin, Haohao},
title = {Engineered Chiral Probiotics Ameliorate MASH via Gut–Liver Axis},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.78432}
}
EUVIMED